Dendreon (pink sheets,dow jones:DNDN) Is scheduled to report second quarter results on August 3 and will hold a business call at 4:30 to talk about www.therapywithfigs.com
results. The overwhelming factor to watch for in the second quarter is the level of Provenge sales. Based on owners guidance, Wall Street is looking to get about $55 to $65 million of vertexhealthandfitness.com
sales in the 2Q and my expectation is that sales will come in at about $60 million. I also expect know-how to reiterate full year guidance for sales of $350 to $400 million. I am projecting 3Q sales of $99 million and 4Q sales of $188 million which brings my full year estimate in at $375 million. I am not expecting much new concept to move the stock price on this call. Management might provide metrics on account penetration and product usage that could help firm up full year projections, But I don’t think this would have much of an impact on the stock price. I think that the performance of the stock into late this year is almost totally depending on reaching sales guidance for 2011, which could back end loaded.
within second quarter, Favorable developments on reimbursement and manufacturing put these concerns NFL Cheap Jerseys
in the rear view mirror. As year end systems, Focus will shift to estimates for 2012 sales productivity, Which are highly relying on reaching the back end loaded sales goal for 2011 that will establish a base for entering 2012. Wall Street analysts buy jerseys
always have different judgments on item launches, But on Provenge there appears to be much more divergence than usual with vocal bears and bulls. I keep on being a buyer of the stock. Please refer to the ten reports that I showed on Dendreon this year for more specific information.
Dendreon had a very encouraging second quarter in regards to refund issues. The CMS issued its final coverage decision on Provenge repayment and the company received a product specific Q code effective July 1, 2011. Concerns about compensation did have a negative effect on physician prescribing in the first half of the year. At a list expense of $31,000 per dose and three doses per length of therapy, files receivable can build very rapidly. Now accounts can have a very high level of confidence that it they prescribe Provenge on label, it could be paid for. on top, The Q code should speed up the compensation cycle.
On another incredibly good note, The Los Angeles manufacturing unit has been approved and the Atlanta facility should be approved in late August. This might be a faster than I expected. In terms of making capacity, towards the end of 2Q, 2011 or between 3Q, 2011, The original manufacturing facility in New jersey should have 48 workstations. This would be four times its capacity afterwards of 2010. The Atlanta and Los Angeles facilities could eventually have 36 workstations. They will be brought on in a staged fashion so that by the end of the season, Dendreon should have 120 work stations in the three plants. This is 10 times as large as the 12 stations in New jersey that were detailed at the end of 2010. business has been supply constrained since launch, But it now has ample capacity to simply meet and exceed its sales guidance.